《新股表現》凱萊英(06821.HK)暗盤高開1%報392元
根據輝立交易平臺顯示,明天(10日)掛牌的凱萊英(06821.HK)暗盤高開1%報392元欠承接,掉頭低見360元,現報361元,較上市價388元,低7%,成交1.8萬股。
凱萊英是領先技術區動型(CDMO)公司,提供貫穿藥物開發及生產全過程的綜合解決方案。根據弗若斯特沙利文資料,按2020年收入計,凱萊英爲全球第五大原料藥CDMO,擁有1.5%市場份額,且爲總部位於內地的最大型商業化階段化學藥物CDMO,擁有22%市場份額。
凱萊英是次來港上市共發售1,841.54萬股,其中10%公開發售獲0.6倍超購,人人有份,股份以高於招股範圍(350-410元)中間位定價,料集資淨額68.5億元,主要用作進一步提高小分子CDMO解決方案的產能與能力、加強公司新興服務並擴大服務範圍、投資研發項目及保持公司技術領先地位、選擇性進行戰略投資及收購等。上市聯席保薦人分別爲高盛及中信證券。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.